Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
Fuji
Boehringer Ingelheim
Teva
US Department of Justice
UBS
McKinsey
Chubb

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for United Kingdom Supplementary Protection Certificate: SPC/GB09/055

« Back to Dashboard

Country Document Number Supplementary Protection Certificate SPC Country SPC Description SPC Expiration
European Patent Office 0451216 SPC/GB09/055 United Kingdom PRODUCT NAME: CERTOLIZUMAB PEGOL; REGISTERED: UK EU/1/09/544/001 20091001; UK EU/1/09/544/002 20091001; REASON FOR LAPSE: SURRENDERED ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Medtronic
Harvard Business School
Express Scripts
Farmers Insurance
Fish and Richardson
AstraZeneca
Federal Trade Commission
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.